Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72. 3) in patients with carcinoma

Journal Article · Sat Aug 01 04:00:00 EDT 1987 · Cancer Res.; (United States)

OSTI ID:6177092

Colcher, D; Esteban, J; Carrasquillo, J A; Sugarbaker, P; Reynolds, J C; Bryant, G; Larson, S M; Schlom, J

Monoclonal antibody (MAb) B72.3 has been shown to have selective reactivity for a wide range of carcinomas (colorectal, ovarian, breast, lung, gastric, and endometrial) versus normal adult tissues. /sup 131/I-Labeled B72.3 IgG has recently been shown to selectively bind carcinoma lesions when administered i.v. in patients with metastatic colorectal cancer. We report here the first direct comparison of i.p. administered (/sup 131/I)B72.3 IgG to specifically localize metastatic carcinoma. Three of 10 patients studied were negative for tumor detection by both CAT scan and X-ray but were positive for tumor localization via gamma scanning i.p. administered /sup 131/I-labeled MAb B72.3 IgG. Direct analyses of biopsy specimens of carcinoma and normal tissues demonstrated ratios of greater than 70:1 (based on percentage of injected dose/mg) for tumor MAb localization versus normal tissues. Specificity of (/sup 131/I)B72.3 tumor targeting was demonstrated by the concomitant administration of an equal dose of an /sup 125/I-labeled isotype identical (IgG1) control MAb. Simultaneous i.p. administration of (/sup 131/I)B72.3, and i.v. administration of (/sup 125/I)B72.3 in individual patients demonstrated: peritoneal implants are targeted more efficiently via i.p. MAb administration, and hematogenously spread and lymph node metastases as well as local recurrences are targeted more efficiently by i.v. administered MAb. No antibody toxicity was observed in any patients. Pharmacokinetics of MAb clearance demonstrated that only 10 to 30% of the i.p. administered MAb was found in plasma. These studies thus demonstrate the efficacy of intracavitary MAb administration as well as the advantage of the concomitant use of intracavitary and i.v. administered MAbs for tumor targeting and for potential MAb guided therapy of metastatic carcinoma.

• Research Organization: National Cancer Institute, Bethesda, MD
• OSTI ID: 6177092
• Journal Information: Cancer Res.; (United States), Journal Name: Cancer Res.; (United States) Vol. 47:15; ISSN CNREA
• Country of Publication: United States
• Language: English

Related Subjects

550604* -- Medicine-- Unsealed Radionuclides in Therapy-- (1980-)
62 RADIOLOGY AND NUCLEAR MEDICINE
ANTIBODIES
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BIOLOGICAL LOCALIZATION
CARCINOMAS
CLEARANCE
DAYS LIVING RADIOISOTOPES
DISEASES
ELECTRON CAPTURE RADIOISOTOPES
IMMUNOTHERAPY
INJECTION
INTAKE
INTERMEDIATE MASS NUCLEI
INTRAPERITONEAL INJECTION
INTRAVENOUS INJECTION
IODINE 125
IODINE 131
IODINE ISOTOPES
ISOTOPES
LABELLING
MEDICINE
METASTASES
MONOCLONAL ANTIBODIES
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
ODD-EVEN NUCLEI
PATIENTS
RADIOISOTOPES
RADIOLOGY
RADIOTHERAPY
SPECIFICITY
THERAPEUTIC USES
THERAPY
USES